Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00192075 · ClinicalTrials.gov registry record · Phase 2
A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT00192075 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 84 participants.
The verdict
NCT00192075, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of the study is to describe the tumor response rates for the two regimens being studied, and to determine how long patients live after receiving the treatment, how long patients are without return of their disease after they receive treatment, and how long the response they get from the treatment lasts. The amount and type of side effects/toxicities of each regimen will also be evaluated. The regimen including Oxaliplatin + 5FU/Folinic Acid is a current standard of care.
Interventions
- DRUG Gemcitabine
- DRUG oxaliplatin
- DRUG avastin
- DRUG 5FU/folinic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2003-06 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00192075
The ClinicalTrials.gov registry entry for NCT00192075 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Gemcitabine is the first listed.
NCT00192075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00192075 about?
NCT00192075 is a clinical study titled "A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer". The purpose of the study is to describe the tumor response rates for the two regimens being studied, and to determine how long patients live after receiving the treatment, how long patients are without return of their disease after they receive treatment, and how long the response they get from the ...
What is the current status of trial NCT00192075?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2003-06. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00192075?
The interventions under investigation include: Gemcitabine (DRUG), oxaliplatin (DRUG), avastin (DRUG), 5FU/folinic acid (DRUG).
Who is sponsoring clinical trial NCT00192075?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.